## **Sultanate of Oman Ministry of Health Drug Safety Center** Muscat



وزارة الصحــة مركز سلامة الدواء

Circular No.

8 / 2025 Joving Forward

27 -07-1446 H 27 -01-2025

## Field Safety Notice of HemosIL Heparin Calibrators from Werfen.

Source	SFDA- Saudi Food & Drug Authority <a href="https://ade.sfda.gov.sa/Fsca/PublishDetails/231">https://ade.sfda.gov.sa/Fsca/PublishDetails/231</a>			
Product	HemosIL Heparin Calibrators.			
Manufacturer	Werfen.			
Local agent	Muscat Pharmacy & Stores LLC.			
The affected products	Part No. 0020300600. UDI-DI: 08426950472483. Please see Appendix A of the attachment for a list of in-date lots with corrected value assignments for the HEP CAL 2 and HEP CAL 3 levels.			
Reason	The potential of heparin controls reporting low out of their assigned acceptance range with HemosIL Liquid Anti-Xa (Part Nos. 0020302600, 0020302602, 0020303600), leading to delays in patient testing.			
Action	<ol> <li>Please follow "Mandatory Customer Actions" in the attachment.</li> <li>Contact the local agent for remedial action.</li> </ol>			
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: <a href="mailto:vigilance-md@moh.gov.om">vigilance-md@moh.gov.om</a>			

Dr. Mohammed Hamdan Al Rubaie **Director General** 







ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩ P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489 

Sultanate of Oman Ministry of Health Drug Safety Center Muscat



سلطنة عُمان وزارة الصحة مركز سلامة الدواء مسقط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

**Director General of Royal Hospital** 

**Director General of Khoula Hospital** 

**Director General of Medical Supplies (MOH)** 

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No <u>8</u> dated <u>27/1/2025</u> Regarding SFDA Field Safety Notice of HemosIL Heparin Calibrators from (mfr: Werfen).

### Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DSC
- Director of Pharmacovigilance & Drug Information Dept, DSC
- Director of Drug Control Department, DSC
- Director of Pharmaceutical Licensing Department, DSC
- · Director of Central Quality Control Lab., DSC
- Supdt. of Central Drug Information







### **URGENT FIELD SAFETY NOTICE**

# HemosIL Heparin Calibrators Part No. 0020300600 – All In-Date Lots (See Appendix A)

December 18, 2024

Dear Valued HemosIL® Liquid Anti-Xa Customer:

This notification is intended to advise your facility regarding an unfractionated heparin (UFH) and low molecular weight heparin (LMWH) performance issue with HemosIL Liquid Anti-Xa (Part Nos. 0020302600, 0020302602, 0020303600) that is due to a bias against the WHO International Standards for UFH and LMWH with in-date lots of HemosIL Heparin Calibrators (Part No. 0020300600, UDI-DI 08426950472483).

See Appendix A at the end of this notification for a list of in-date calibrator lots with corrected values.

#### **Issue Description and Impact**

We have received customer complaints of heparin controls reporting low out of their assigned acceptance range with HemosIL Liquid Anti-Xa, leading to delays in patient testing. Our internal investigation has identified that the value assignment of the HemosIL Heparin Calibrators has shown a bias against the WHO International Standards for UFH and LMWH, potentially causing reduced recovery when measuring heparin on both controls and samples.

Note: Apixaban and rivaroxaban measurements with HemosIL Liquid Anti-Xa are unaffected as these tests use different calibrators.

To ensure accurate heparin reporting, customers must follow the instructions below to update the calibrator values for Heparin Calibrator 2 (HEP CAL 2) and Heparin Calibrator 3 (HEP CAL 3) in the ACL TOP test parameters (all instrument models: ACL TOP Family, ACL TOP Family 50 Series, and ACL TOP Family 70 Series) using the corrected values provided in Appendix A. The Heparin Calibrator 1 (HEP CAL 1) level remains unchanged as 0.00 IU/mL.

We will also verify the value assignments for on-market lots of HemosIL UF Heparin Controls (Part No. 0020300300) and HemosIL Low Molecular Weight Heparin Controls (Part No. 0020300200) using a representative reagent lot recalibrated based on the corrected HEP CAL 2 and HEP CAL 3 values. If needed, we will provide new acceptance ranges for these controls to you. Until then, perform quality control testing per labeled instructions for use. If the HemosIL UF Heparin Controls or HemosIL Low Molecular Weight Heparin Controls recover out of the lot-specific acceptance ranges, determine your own control ranges per your internal protocol.

# werfen

### **Mandatory Customer Actions**

Based on the above, please take the following immediate actions:

- Check inventory for lots of HemosIL Heparin Calibrators (Part No. 0020300600). See Appendix A for a list of in-date lots with corrected value assignments for the HEP CAL 2 and HEP CAL 3 levels.
- Follow the instructions below to update the ACL TOP test parameters (same instructions for all models):
  - Select "Setup" from the menu bar and then select "Test List" from the dropdown menu.
  - From "Test List", double click on the Test Code "Anti-Xa" to open "Test Definition Anti-Xa".
  - From "Test Definition Anti-Xa, click on "Pre-diluted calibrators" under the header "Calibration". An editable table titled "Calibration points" will appear with HEP CAL 1, HEP CAL 2, and HEP CAL 3 and their predefined "Target Values IU/mL" of 0.00, 0.80 and 2.00, respectively.
  - In the "Calibration points" table, change the target values for HEP CAL 2 and HEP CAL 3 to the lot-specific calibrator values provided in Appendix A.
  - After entering the corrected HEP CAL 2 and HEP CAL 3 values, click on the save icon (picture of floppy disk) to save the changes.
- Recalibrate using the HemosIL Liquid Anti-Xa assay lot in use after making the test parameter update.
- Run quality controls per labeled instructions for use. If needed, determine control ranges for HemoslL UF Heparin
  Controls (Part No. 0020300300) and HemoslL Low Molecular Weight Heparin Controls (Part No. 0020300200) in
  accordance with your internal protocol until the new acceptance ranges are available.
- Repeat the above test parameter update, recalibration, and quality control for all ACL TOP instruments.
- Share this information with your laboratory staff.
- Forward this notification to all affected locations within your facility.
- Retain a copy of this notification for your records.

We appreciate your prompt attention to this Urgent Field Safety Notice. Sincerely,

Anuja Khan

Regulatory Affairs Manager II Instrumentation Laboratory Co.

Amijolekan

A Werfen Company

# werfen

### Appendix A

HemosIL Heparin Calibrators, Part No. 0020300600 (UDI-DI: 08426950472483)

### In-date Lots with Corrected HEP CAL 2 and HEP CAL 3 Values

Lot No.	Manufactured Date (YYYY-MM-DD)	Expiration Date (YYYY-MM-DD)	HEP CAL 2 Corrected Value (IU/mL)	HEP CAL 3 Corrected Value (IU/mL)
N0128933	2022-02-01	2025-01-31	0.88	2.15
N0220450	2022-03-01	2025-02-28	0.90	2.31
N0522479	2022-06-01	2025-05-31	0.91	2.12
N0724070	2022-08-01	2025-07-31	0.86	2.21
N1026509	2022-11-01	2025-10-31	0.90	2.18
N0239584	2023-03-01	2026-02-28	0.89	2.24
N0531891	2023-06-01	2026-05-31	0.88	2.23
N0733658	2023-08-01	2026-07-31	0.90	2.24
N0249207	2024-03-01	2027-02-28	0.89	2.22
N0442161	2024-05-01	2027-04-30	0.87	2.24
N0744673	2024-08-01	2027-07-31	0.90	2.30